Organon has begun an executive search for a new chief executive officer following the resignation of Kevin Ali. The leadership change came after the board’s audit committee completed a probe into the company’s wholesaler sales practices relating to Nexplanon, a popular birth control implant. The investigation determined that certain U.S. wholesalers were encouraged to purchase more product than they needed across multiple quarters from 2022 to 2025, which accounted for less than 1% of Organon’s annual consolidated revenue for those years but helped the company meet external guidance and revenue goals.
As a result, Ali will depart the company without severance or retirement benefits tied to equity. Joseph Morrissey, previously executive vice president and head of manufacturing and supply, was named interim CEO. Board Chair Carrie S. Cox is assuming expanded responsibilities as executive chair during the search, which will consider both internal and external candidates. Organon also terminated its head of U.S. commercial operations as part of its response to the findings.
The company stated that while the sales actions were improper and led to inaccurate disclosures in some previous statements, no restatements of financials are needed. Organon has since initiated corrective measures to strengthen financial oversight and internal controls to restore stakeholder confidence in its business practices.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!